Coronary stent thrombosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Smitakohli (talk | contribs) No edit summary |
||
| Line 8: | Line 8: | ||
{{Editor Help}} | {{Editor Help}} | ||
==Introduction== | ==[[Introduction]]== | ||
==[[Definitions - coronary stent thombosis (ST)]]== | ==[[Definitions - coronary stent thombosis (ST)]]== | ||
==[[Mechanism and pathophysiology of coronary stent thrombosis (ST)]]== | ==[[Mechanism and pathophysiology of coronary stent thrombosis (ST)]]== | ||
==[[Incidence of coronary stent thrombosis (ST) in bare metal stents (BMS)]]== | ==[[Incidence of coronary stent thrombosis (ST) in bare metal stents (BMS)]]== | ||
==[[Incidence of coronary stent thrombosis (ST) in drug eluting stents (DES)]]== | ==[[Incidence of coronary stent thrombosis (ST) in drug eluting stents (DES)]]== | ||
==[[Incidence of drug eluting stent thrombosis (ST) in relation to antiplatelet medication use]]== | ==[[Incidence of drug eluting stent thrombosis (ST) in relation to antiplatelet medication use]]== | ||
==[[Future Directions]]== | |||
== | |||
At the request of the FDA, four major drug companies and four major device companies are jointly investigating the best strategy to avoid clot formation in patients that have received stents. The $100 million, four-year study of 20,000 patients will specifically examine whether patients should remain on blood-thinners for 1 or 2.5+ years after PCI. Companies involved include: Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Daiichi Sankyo, Abbott, Medtronic, Boston Scientific, and Johnson & Johnson. This study was presented at TCT 2008 by Dr. Laura Mauri, a co-principal investigator of the study.<ref>http://online.wsj.com/article/SB122411707038238773.html?mod=rss_whats_news_us_busines</ref> | At the request of the FDA, four major drug companies and four major device companies are jointly investigating the best strategy to avoid clot formation in patients that have received stents. The $100 million, four-year study of 20,000 patients will specifically examine whether patients should remain on blood-thinners for 1 or 2.5+ years after PCI. Companies involved include: Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Daiichi Sankyo, Abbott, Medtronic, Boston Scientific, and Johnson & Johnson. This study was presented at TCT 2008 by Dr. Laura Mauri, a co-principal investigator of the study.<ref>http://online.wsj.com/article/SB122411707038238773.html?mod=rss_whats_news_us_busines</ref> | ||
Revision as of 14:14, 15 December 2009
| Cardiology Network |
 Discuss Coronary stent thrombosis further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
Editors-In-Chief: Allen Jeremias, M.D., SUNY; Don Cutlip, M.D. Beth Israel Deaconess Medical Center, Harvard
Associate Editors-In-Chief: Priyantha Ranaweera, M.D.; William J. Gibson, MIT
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Introduction
Definitions - coronary stent thombosis (ST)
Mechanism and pathophysiology of coronary stent thrombosis (ST)
Incidence of coronary stent thrombosis (ST) in bare metal stents (BMS)
Incidence of coronary stent thrombosis (ST) in drug eluting stents (DES)
Incidence of drug eluting stent thrombosis (ST) in relation to antiplatelet medication use
Future Directions
At the request of the FDA, four major drug companies and four major device companies are jointly investigating the best strategy to avoid clot formation in patients that have received stents. The $100 million, four-year study of 20,000 patients will specifically examine whether patients should remain on blood-thinners for 1 or 2.5+ years after PCI. Companies involved include: Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, Daiichi Sankyo, Abbott, Medtronic, Boston Scientific, and Johnson & Johnson. This study was presented at TCT 2008 by Dr. Laura Mauri, a co-principal investigator of the study.[1]
References
Additional Resources
- Singh M Et al. Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current eta (the mayo clinc experince). Am J Cardiol 2001;88:1091-6
- White CJ et al. Coronary thrombi increase PTCA risk. Angioscopy as a clinicla tool. Circulation 1996;93:253-8
- G Sianos, et al. Angiographic stent thrombosis after routine use of drug eluting stents in ST -Segement elevation myocardial infarction, the importance of thrombus burden. JACC, Vol 50, No 7, 2007
- C. Spaulding, et al. Sirolimus-Eluting versus Uncoated Stents in acute myocardial infarction, N Engl J Med 2006;355:1093-104.
- Menichelli M . Sirolimus stent versus bare stent in acute myocardial infarction trail, Presented at European Percutaneou Cororanry Revascularizaton 2006.
External links
- The MD TV: Comments on Hot Topics, State of the Art Presentations in Cardiovascular Medicine, Expert Reviews on Cardiovascular Research
- Clinical Trial Results: An up to dated resource of Cardiovascular Research